Category: ODD/BTA/FTA Status Region: North America · United States Company: Merck And Co Inc

Us Fda Grants Breakthrough Therapy Designation To Mercks 21-Valent Pneumococcal Conjugate Vaccine V116 To Treat Ipd & Pneumococcal Pneumonia

Us Fda Grants Breakthrough Therapy Designation To Mercks 21-Valent Pneumococcal Conjugate Vaccine V116 To Treat Ipd & Pneumococcal Pneumonia
Merck, Known As Msd Outside The United States And Canada, Announced That V116, The Company

Found this useful? Share it with your team.

Welcome Back Sign in to Continue

Don't Have an Account? Sign Up!
Forgot Password?

Create your Account!

Don't Have an Account? Sign Up!